Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Non-Current Deffered Revenue: 2022-2024

Historic Non-Current Deffered Revenue for Praxis Precision Medicines (PRAX) over the last 2 years, with Sep 2024 value amounting to $293,000.

  • Praxis Precision Medicines' Non-Current Deffered Revenue fell 80.67% to $293,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $293,000, marking a year-over-year decrease of 80.67%. This contributed to the annual value of $1.2 million for FY2023, which is 46.79% down from last year.
  • Praxis Precision Medicines' Non-Current Deffered Revenue amounted to $293,000 in Q3 2024, which was down 50.17% from $588,000 recorded in Q2 2024.
  • Praxis Precision Medicines' Non-Current Deffered Revenue's 5-year high stood at $2.2 million during Q4 2022, with a 5-year trough of $293,000 in Q3 2024.
  • Its 3-year average for Non-Current Deffered Revenue is $1.2 million, with a median of $1.3 million in 2023.
  • Data for Praxis Precision Medicines' Non-Current Deffered Revenue shows a maximum YoY tumbled of 80.67% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Praxis Precision Medicines' Non-Current Deffered Revenue stood at $2.2 million in 2022, then crashed by 46.79% to $1.2 million in 2023, then tumbled by 80.67% to $293,000 in 2024.
  • Its last three reported values are $293,000 in Q3 2024, $588,000 for Q2 2024, and $866,000 during Q1 2024.